Selexis and Inotrem Enter Service Agreement to Advance Inotrem’s Chronic Inflammatory Disease ProgramRead More
Valérie joined Selexis in 2010. Currently, she is head of Cell Culture, where she addresses specific secretion bottlenecks of difficult-to-express recombinant proteins.
Valérie received her PhD from the University of Aix-Marseille II, where she focused on hTPO maturation and the role of ER chaperones in the folding/degradation machineries of this difficult-to-express glycoprotein. After completing her PhD, Valérie held a postdoctoral position at the UniversitätsSpital Zürich (Cell and Molecular Pathology Department) where she described a selective autophagy-mediated mechanism of misfolded and aggregated proteins that are retained in the ER compartment.
Explore the SUREtechnology Platform™
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving mAb therapeutics into the clinic and to the market.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Copyright© 2022 Selexis SA. All Rights Reserved.